Rhino Therapeutics
Organisation
People
Sources: reporter.nih.gov
Grants and prizes
Collaborative R&D, Rhino Therapeutics: pre-clinical model development and efficacy testing of the first disease-modifying therapy globally to restore sensorineural olfactory loss and improve patient outcomes and quality of life, 10143262, £464.8k, 2025–2026, 1 Jun 2025
National Institute on Deafness and Other Communication Disorders
R41, Evaluation of siRNA based drugs as pro-regenerative disease-modifying therapeutics for age-related olfactory loss, R41DC021592, US$295.7k, 2024–2025, 15 May 2024
Sources: gtr.ukri.org, reporter.nih.gov